International Comparison of Smoking and Metabolic Control in Patients With Type 1 Diabetes
Smoking may influence metabolic control and increase the risk of vascular complications in type 1 diabetes (T1D) (1,2). Antismoking public health policy may influence smoking habits in the population with diabetes; therefore, different behaviors between Europe and the U.S. may be expected (3,4). The T1D Exchange Registry (T1DX) in the U.S. and the Prospective Diabetes Follow-up Registry (DPV) in Germany and Austria are two large consortia of diabetes centers, which used their data sets to describe the prevalence of smoking habits in adults with T1D and analyzed the relationship between smoking status and metabolic outcomes.
Our analyses include 20,405 patients with T1D aged ≥18 years and with T1D duration ≥1 year (10,579 participants from 65 T1DX centers and 9,826 participants from 297 DPV centers). Smoking status was defined by smoking at least one cigarette per day, former smokers reported smoking in the past, and nonsmokers never smoked. Smoking data were self-reported in both registries.
Wilcoxon or χ-square tests were used for unadjusted comparisons between registries and between smoking groups. Smoking rates adjusted for age-group and sex were compared between registries using multinomial logistic regression models. Hierarchical linear regression models were run to examine associations between smoking status and clinical outcomes within each registry.
Patients from both registries were similar with respect to age and HbA1c. The proportion of smokers in T1DX and DPV was 10.0% vs. 24.3% (P < 0.001); of former smokers, 18.1% vs. 5.1% (P < 0.001); and of nonsmokers, 72.0% vs. 70.6% (P < 0.001). The number of smokers was significantly higher across all ages in DPV (Fig. 1), smokers were more likely male than female (T1DX 12.0% vs. 9.0%, P < 0.001; DPV 27.7% vs. 20.3%, P < 0.001), and the majority of smokers were under the age of 50 years (80.0% in T1DX and 77.9% in DPV). Smokers had significantly higher HbA1c levels (8.5% vs. 7.9% [70 vs. 62 mmol/mol], P < 0.001) after adjustment for age-group, sex, T1D duration, and migration background/not non-Hispanic white. Smokers showed an unfavorable lipid profile with significantly higher triglycerides (1.62 vs. 1.35 mmol/L, P < 0.0001) after adjustment for age, sex, diabetes duration, BMI, and lipid-lowering medication and had higher LDL levels (2.78 vs. 2.67 mmol/L, adjusted P < 0.0001).
Treatment strategies in T1D focus on glycemic control as the main treatment goal. Our data clearly show higher HbA1c and additional unfavorable lipid profiles in patients with T1D who smoke. The proportion of smokers was significantly higher in DPV, peaking at 35% in 26- to 50-year-olds. We observed a significantly higher number of former smokers in the U.S., implying that interventions to reduce tobacco consumption and smoke-free policies have been more successful in the U.S. compared with Europe. The high proportion of smokers in DPV and the low number of former smokers (6%) clearly show that further activities toward tobacco cessation are needed in Europe. Possible limitations are differences in data collection methods between registries (population based in DPV and center based in T1DX) and assessment of smoking status by self-report (5).
Funding. This work was supported through the Leona M. and Harry B. Helmsley Charitable Trust; the German BMBF Competence Network Diabetes Mellitus (FKZ 01GI1106), which is integrated into the German Center for Diabetes Research as of January 2015; and the European Foundation for the Study of Diabetes.
Duality of Interest. No potential conflicts of interest relevant to this article were reported.
Author Contributions. S.E.H., J.M.H., and R.W.H. researched the data, performed data analysis, and contributed to data interpretation and the writing of the manuscript. K.M., D.J.D., I.B.H., R.W.B., and D.M.M. researched the data and contributed to data interpretation and the writing of the manuscript. M.R. and W.K. contributed to data collection in Austria and Germany and contributed to data interpretation and the writing of the manuscript. All authors approved the final version. R.W.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
↵* A complete list of the members of the DPV Initiative and T1D Exchange Clinic Network can be found in the Supplementary Data online.
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-0845/-/DC1.
- Received April 19, 2016.
- Accepted July 20, 2016.
- © 2016 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.